Sponsors are shedding light on our expertise with infectious diseases
e-Bulletin | October 2015
"In less than three months, Algorithme Pharma completed the first part of our study in sequential dose escalation of 48 Healthy Volunteers and 15 Genotype1 hepatitis C virus (HCV) infected subjects. In a highly competitive environment, they also successfully participated in the multiple dosing of several genotype HCV infected subjects, and delivered six subjects within two months."
— Marie-Françoise TEMAM
Associate Director, Clinical Operations, Idenix, a wholly-owned subsidiary of Merck & Company Partnered with Algorithme Pharma on a Proof of Concept Phase I/IIa Hepatic C Virus Infection Study.
Read the full testimonial and learn more about our therapeutic expertise.